DICK’S Sporting Goods Announces Participation in the Goldman Sachs 32nd Annual Global Retailing Conference

DICK'S Sporting Goods, Inc. (NYSE: DKS) today announced that management will participate in a fireside chat at the Goldman Sachs 32nd Annual Global Retailing Conference on Thursday, September 4th at 11:40 a.m. Eastern Time. https://mma.prnewswire.com/media/479785/DICKS_Sporting_Goods_Logo.jpg The event will be webcast and can be accessed live or as an archived replay from the link on the […]

Kinomica Expands IP Portfolio to 45 Granted Patents with New Assignments from QMUL, Strengthening Leadership in Phosphoproteomics

Kinomica Ltd., a clinical diagnostics company pioneering phosphoproteomic biomarkers to enable precision oncology, today announced the assignment of two key patent families from Queen Mary University of London (QMUL). The assignment, completed on August 18, 2025, further strengthens Kinomica's position as the global leader in phosphoproteomic intellectual property. https://mma.prnewswire.com/media/2755319/Kinomica_Logo.jpg With these additions, Kinomica's portfolio now

Small Businesses Show Tariff-Proof Resilience, GoDaddy Survey Finds

Two-thirds of U.S. small businesses report zero international exposure Global economic uncertainty, fuelled by trade negotiations, tariff escalations, and supply chain challenges, continues to put pressure on many U.S. small businesses – particularly those with international exposure. Yet new findings from the GoDaddy Small Business Research Lab reveal a different story among domestic-focused microbusinesses. https://mma.prnewswire.com/media/2755232/3_GoDaddy_Small_Business_Research_Lab_Summer_2025_Survey_Rev_Change_Over_next_6_months_blog_highres_Infographic.jpg

ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care. ZEISS Medical Technology today announced CE mark approval for CIRRUS® PathFinder™, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician's

INVESTOR DEADLINE MONDAY: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – HIMS

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the “Class Period”), have until this Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit.

Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- Initial results from safety sentinel cohort expected in 2H 2026- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the first child has

Mount Sinai South Nassau Expands Anesthesia Services With Selection of Greater New York Anesthesia Services Group

Mount Sinai South Nassau is expanding anesthesia services as its role as a teaching hospital grows. The expansion is being supported by Greater New York Anesthesia Services, P.C. (GNYAS), which will provide full anesthesia services for the Oceanside-based hospital. Mount Sinai South Nassau is a 455-bed hospital located in Oceanside, New York that currently runs

Block O’Toole & Murphy Partner Daniel P. O’Toole Named Best Lawyers® 2026 “Lawyer of the Year” for Personal Injury – Plaintiff in New York City

Daniel P. O'Toole, managing partner of the premier New York law firm Block O'Toole & Murphy, has been named the New York City 2026 “Lawyer of the Year” in Personal Injury Litigation – Plaintiff by Best Lawyers®. This incredible honor is only awarded to one attorney per year in each practice area and geographic region.

BioDlink’s Bevacizumab Approved for Market Launch in Indonesia, Marking Fourth Consecutive Emerging Market Authorization

— Bevacizumab Injection officially approved by Indonesia's National Agency of Drug and Food Control (BPOM), following Nigeria, Pakistan, and Colombia – accelerating global commercialization — Approval in ASEAN's largest pharma market strengthens BioDlink's position as a global supplier of antibody/XDC therapies via international GMP standards and commercial capabilities https://mma.prnewswire.com/media/2682341/BioDlink_EN_Logo.jpg SUZHOU, China, Aug. 21, 2025 /PRNewswire/–BioDlink

SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health

— Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea. — Both reviews expanded cooperation, including next-generation preventive medicines. SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company held an exclusive meeting with the Gates

Scroll to Top